Clinical Trials
Emisphere completes enrollment for Phase II oral insulin clinical trial
Published in Obesity and Diabetes Week, May 8th, 2006
By expanding the trial, Emisphere will be able to evaluate the performance of all three active arms of the trial against each other for statistical significance. Without the additional patients, Emisphere would have been limited to evaluating each of the active arms against only the placebo for statistical significance. Based on the current enrollment rate, the company expects to complete the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Diet & Nutrition
Orexigenic peptides are overexpressed after early life exposure to fat-rich diet - Obesity Complications
Body mass index contributes to both baseline and weight loss white blood cell count - Obesity Pathogenesis
GABAA receptor antagonists prevent defects in leptin, insulin and amylin actions in obese - Obesity Pathogenesis
Plasma antioxidant capacity values are impaired in morbidly obese patients - Obesity Therapy
Increased serum amyloid A levels in morbid obesity decrease after gastric bypass - Angiology
New data from the People's Republic of China, United States and Germany lluminates research in angiology - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
